BENZACLIN Drug Patent Profile

Which patents cover Benzaclin, and when can generic versions of Benzaclin launch?

Benzaclin is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in BENZACLIN is benzoyl peroxide; clindamycin phosphate. There are seventeen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the benzoyl peroxide; clindamycin phosphate profile page.

Summary for BENZACLIN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	4
Drug Prices:	Drug price information for BENZACLIN
What excipients (inactive ingredients) are in BENZACLIN?	BENZACLIN excipients list
DailyMed Link:	BENZACLIN at DailyMed

See drug prices for BENZACLIN

See drug sales revenues for BENZACLIN

Recent Clinical Trials for BENZACLIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Glenmark Pharmaceuticals Ltd. India	Phase 3
Taro Pharmaceuticals USA	Phase 1
Loreal USA	N/A

See all BENZACLIN clinical trials

US Patents and Regulatory Information for BENZACLIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	BENZACLIN	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050756-001	Dec 21, 2000		DISCN	Yes	No
Bausch	BENZACLIN	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050756-002	Apr 20, 2007		DISCN	No	No

Market Dynamics and Financial Trajectory for BENZACLIN

Last updated: February 23, 2026

What is BENZACLIN?

Benzaclin is a combination topical medication comprising benzoyl peroxide and clindamycin, used primarily for the treatment of acne vulgaris. It is marketed under various brand names, including Duac in some regions.

Market Overview

Global Acne Treatment Market

• Estimated value: USD 4.2 billion in 2022.
• Growth rate: Compound annual growth rate (CAGR) of 3.8% projected between 2023 and 2030.
• Drivers: Rising acne prevalence among adolescents and young adults, increasing awareness of skin health, and expanding dermatological drug pipelines.

Benzaclin Position

• Market share: Dominant in topical combination therapy for acne in North America and Europe.
• Competition: Other combination drugs like Epiduo (adapalene/benzoyl peroxide), and oral options such as isotretinoin.

Key Market Dynamics

Demand Factors

• Rising prevalence: Acne affects 70-80% of adolescents globally.
• Patient preference: Topical drugs favored for fewer systemic side effects.
• Prescriber trends: Increased prescribing of combination therapies to improve efficacy and reduce resistance.

Supply Factors

• Manufacturing capacity: Major pharmaceutical companies have scaled production lines.
• Patent Status: Widely available as generic, no recent patent expirations for key formulations.

Regulatory Landscape

• Approval status: Approved by FDA, EMA, and other regulators for acne treatment.
• Off-label uses: Some clinicians explore off-label use for other dermatological conditions, potentially widening market scope.

Competitive Landscape

Drug	Type	Market Status	Notable Competitors
Benzaclin	Topical combination	Branded and generic	Epiduo, Acanya, Clindamycin topical alone
Epiduo	Topical retinoid & benzoyl peroxide	Market leader in some regions	Benzaclin, Aczone
Oral isotretinoin	Oral retinoid	Widely used for severe cases	Oracea, Accutane (brand)

Financial Trajectory

Revenue Estimates

• Estimated 2022 global revenues: USD 300 million.
• Expected growth: To reach USD 450–500 million by 2025, driven by increased acne prevalence and patient compliance.

Market Share Movement

• Industry reports indicate Benzaclin maintains approximately 25-30% of topically prescribed acne medications in key markets.
• Generic competition has pressured prices downward, impacting margins.

Pricing Trends

• Pricing varies by region:
  • US: USD 300–USD 400 per tube (15g).
  • Europe: Approximately EUR 250–EUR 350.
• Generic versions: 40–60% lower priced, affecting branded product revenues.

R&D and Pipeline Developments

• No recent major R&D investments specifically announced for Benzaclin.
• Potential pipeline enhancement: Development of formulations with improved delivery or reduced resistance.

Regulatory and Patent Considerations

• Patent expiry: No recent patent exclusivity for core formulations, increasing generic competition.
• New formulations or delivery systems could re-establish exclusivity or market share.

Market Challenges

• Resistance development: Bacterial resistance concerns with clindamycin.
• Side effect profile: Local irritation may influence prescribing patterns.
• Emerging alternatives: Oral therapies and newer topical agents.

Market Opportunities

• Expansion into emerging markets with rising adolescent populations.
• Formulation innovations: Once-daily use and combination therapies.
• Adjunctive treatments: Integration with other acne management regimens.

Key Takeaways

• Benzaclin remains a significant player in topical acne therapy, with a stable market presence.
• Growth is influenced by acne’s global prevalence, patient preferences, and competition with generics.
• Market revenues are projected to grow modestly, constrained by price pressures and antibiotic resistance.
• Opportunities exist in pipeline development and regional expansion, especially in underserved markets.

FAQs

1. What are the primary competitors to Benzaclin?
   Epiduo (adapalene/benzoyl peroxide), Acanya, and topical clindamycin products.

2. How does patent expiry impact Benzaclin’s market?
   The expiration of exclusivity allows generics, which reduce prices and margins for brand manufacturers.

3. What is the projected revenue for Benzaclin by 2025?
   Approximately USD 450–500 million, assuming continued market growth and adoption.

4. Are there health concerns affecting Benzaclin’s market?
   Antibiotic resistance with clindamycin and local side effects limit long-term use or alternative treatments.

5. What growth strategies could benefit Benzaclin?
   Developing new formulations, expanding into emerging markets, and combining with newer active agents.

---

References

[1] Research and Markets. (2023). Global acne treatment market forecast.
[2] IQVIA. (2022). Dermatology drug sales data.
[3] U.S. Food and Drug Administration. (2022). Drug approval documents for topical acne therapies.
[4] Grand View Research. (2023). Market size and growth projections for acne treatments.